Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing α1-antitrypsin after systemic delivery

Wanda K. O'Neal, Heshan Zhou, Nuria Morral, Estuardo Aguilar-Cordova, Joseph Pestaner, Claire Langston, Benjamin Mull, Yufen Wang, Arthur L. Beaudet, Brendan Lee

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Second-generation adenoviral vectors, mutated in E2a, have been proposed to decrease host immune responses against transduced cells, reduce toxicity, and increase duration of expression as compared with first-generation vectors deleted only in E1. To test these hypotheses further, we have developed an E2a-deleted adenoviral vector expressing human α1-antitrypsin (hAAT). Toxicity of first-generation and E2a-deleted vectors, as determined by hematological indices, liver function tests, and histological analyses, was evaluated in C3H mice for 21 days after vector administration at increasing doses starting at 1 x 1012 particles/kg. Both vectors induced dose-dependent abnormalities including transient thrombocytopenia, elevated ALT levels in serum, and increased hepatocyte proliferation followed by inflammation and then hypertrophy. Differences in the ratio of particles to plaque-forming units among vector preparations led to differences in hAAT expression at similar particle doses. There were no differences in toxicity between the two vectors when measured at matching levels of hAAT expression. However, the E2a-deleted vector was demonstrated to have slightly reduced hepatocyte toxicity at an intermediate particle dose. This suggests that hepatocyte toxicity is related primarily to viral entry and expression, rather than to the presence of noninfectious particles, and implies that vectors with complete elimination of viral gene expression, such as vectors with all viral coding sequences deleted, are likely to have substantial advantages in terms of safety and toxicity.

Original languageEnglish (US)
Pages (from-to)1587-1598
Number of pages12
JournalHuman Gene Therapy
Volume9
Issue number11
StatePublished - Jul 20 1998
Externally publishedYes

Fingerprint

Toxicology
Hepatocytes
Viral Genes
Inbred C3H Mouse
Liver Function Tests
Thrombocytopenia
Hypertrophy
Inflammation
Safety
Gene Expression
Serum

ASJC Scopus subject areas

  • Genetics

Cite this

O'Neal, W. K., Zhou, H., Morral, N., Aguilar-Cordova, E., Pestaner, J., Langston, C., ... Lee, B. (1998). Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing α1-antitrypsin after systemic delivery. Human Gene Therapy, 9(11), 1587-1598.

Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing α1-antitrypsin after systemic delivery. / O'Neal, Wanda K.; Zhou, Heshan; Morral, Nuria; Aguilar-Cordova, Estuardo; Pestaner, Joseph; Langston, Claire; Mull, Benjamin; Wang, Yufen; Beaudet, Arthur L.; Lee, Brendan.

In: Human Gene Therapy, Vol. 9, No. 11, 20.07.1998, p. 1587-1598.

Research output: Contribution to journalArticle

O'Neal, WK, Zhou, H, Morral, N, Aguilar-Cordova, E, Pestaner, J, Langston, C, Mull, B, Wang, Y, Beaudet, AL & Lee, B 1998, 'Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing α1-antitrypsin after systemic delivery', Human Gene Therapy, vol. 9, no. 11, pp. 1587-1598.
O'Neal, Wanda K. ; Zhou, Heshan ; Morral, Nuria ; Aguilar-Cordova, Estuardo ; Pestaner, Joseph ; Langston, Claire ; Mull, Benjamin ; Wang, Yufen ; Beaudet, Arthur L. ; Lee, Brendan. / Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing α1-antitrypsin after systemic delivery. In: Human Gene Therapy. 1998 ; Vol. 9, No. 11. pp. 1587-1598.
@article{907fbdb25b5043b791f49be0f011e76b,
title = "Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing α1-antitrypsin after systemic delivery",
abstract = "Second-generation adenoviral vectors, mutated in E2a, have been proposed to decrease host immune responses against transduced cells, reduce toxicity, and increase duration of expression as compared with first-generation vectors deleted only in E1. To test these hypotheses further, we have developed an E2a-deleted adenoviral vector expressing human α1-antitrypsin (hAAT). Toxicity of first-generation and E2a-deleted vectors, as determined by hematological indices, liver function tests, and histological analyses, was evaluated in C3H mice for 21 days after vector administration at increasing doses starting at 1 x 1012 particles/kg. Both vectors induced dose-dependent abnormalities including transient thrombocytopenia, elevated ALT levels in serum, and increased hepatocyte proliferation followed by inflammation and then hypertrophy. Differences in the ratio of particles to plaque-forming units among vector preparations led to differences in hAAT expression at similar particle doses. There were no differences in toxicity between the two vectors when measured at matching levels of hAAT expression. However, the E2a-deleted vector was demonstrated to have slightly reduced hepatocyte toxicity at an intermediate particle dose. This suggests that hepatocyte toxicity is related primarily to viral entry and expression, rather than to the presence of noninfectious particles, and implies that vectors with complete elimination of viral gene expression, such as vectors with all viral coding sequences deleted, are likely to have substantial advantages in terms of safety and toxicity.",
author = "O'Neal, {Wanda K.} and Heshan Zhou and Nuria Morral and Estuardo Aguilar-Cordova and Joseph Pestaner and Claire Langston and Benjamin Mull and Yufen Wang and Beaudet, {Arthur L.} and Brendan Lee",
year = "1998",
month = "7",
day = "20",
language = "English (US)",
volume = "9",
pages = "1587--1598",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "11",

}

TY - JOUR

T1 - Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing α1-antitrypsin after systemic delivery

AU - O'Neal, Wanda K.

AU - Zhou, Heshan

AU - Morral, Nuria

AU - Aguilar-Cordova, Estuardo

AU - Pestaner, Joseph

AU - Langston, Claire

AU - Mull, Benjamin

AU - Wang, Yufen

AU - Beaudet, Arthur L.

AU - Lee, Brendan

PY - 1998/7/20

Y1 - 1998/7/20

N2 - Second-generation adenoviral vectors, mutated in E2a, have been proposed to decrease host immune responses against transduced cells, reduce toxicity, and increase duration of expression as compared with first-generation vectors deleted only in E1. To test these hypotheses further, we have developed an E2a-deleted adenoviral vector expressing human α1-antitrypsin (hAAT). Toxicity of first-generation and E2a-deleted vectors, as determined by hematological indices, liver function tests, and histological analyses, was evaluated in C3H mice for 21 days after vector administration at increasing doses starting at 1 x 1012 particles/kg. Both vectors induced dose-dependent abnormalities including transient thrombocytopenia, elevated ALT levels in serum, and increased hepatocyte proliferation followed by inflammation and then hypertrophy. Differences in the ratio of particles to plaque-forming units among vector preparations led to differences in hAAT expression at similar particle doses. There were no differences in toxicity between the two vectors when measured at matching levels of hAAT expression. However, the E2a-deleted vector was demonstrated to have slightly reduced hepatocyte toxicity at an intermediate particle dose. This suggests that hepatocyte toxicity is related primarily to viral entry and expression, rather than to the presence of noninfectious particles, and implies that vectors with complete elimination of viral gene expression, such as vectors with all viral coding sequences deleted, are likely to have substantial advantages in terms of safety and toxicity.

AB - Second-generation adenoviral vectors, mutated in E2a, have been proposed to decrease host immune responses against transduced cells, reduce toxicity, and increase duration of expression as compared with first-generation vectors deleted only in E1. To test these hypotheses further, we have developed an E2a-deleted adenoviral vector expressing human α1-antitrypsin (hAAT). Toxicity of first-generation and E2a-deleted vectors, as determined by hematological indices, liver function tests, and histological analyses, was evaluated in C3H mice for 21 days after vector administration at increasing doses starting at 1 x 1012 particles/kg. Both vectors induced dose-dependent abnormalities including transient thrombocytopenia, elevated ALT levels in serum, and increased hepatocyte proliferation followed by inflammation and then hypertrophy. Differences in the ratio of particles to plaque-forming units among vector preparations led to differences in hAAT expression at similar particle doses. There were no differences in toxicity between the two vectors when measured at matching levels of hAAT expression. However, the E2a-deleted vector was demonstrated to have slightly reduced hepatocyte toxicity at an intermediate particle dose. This suggests that hepatocyte toxicity is related primarily to viral entry and expression, rather than to the presence of noninfectious particles, and implies that vectors with complete elimination of viral gene expression, such as vectors with all viral coding sequences deleted, are likely to have substantial advantages in terms of safety and toxicity.

UR - http://www.scopus.com/inward/record.url?scp=17344374017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17344374017&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 1587

EP - 1598

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 11

ER -